226 related articles for article (PubMed ID: 18333607)
1. Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist.
Lin LS; Ha S; Ball RG; Tsou NN; Castonguay LA; Doss GA; Fong TM; Shen CP; Xiao JC; Goulet MT; Hagmann WK
J Med Chem; 2008 Apr; 51(7):2108-14. PubMed ID: 18333607
[TBL] [Abstract][Full Text] [Related]
2. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents.
Fong TM; Guan XM; Marsh DJ; Shen CP; Stribling DS; Rosko KM; Lao J; Yu H; Feng Y; Xiao JC; Van der Ploeg LH; Goulet MT; Hagmann WK; Lin LS; Lanza TJ; Jewell JP; Liu P; Shah SK; Qi H; Tong X; Wang J; Xu SS; Francis B; Strack AM; MacIntyre DE; Shearman LP
J Pharmacol Exp Ther; 2007 Jun; 321(3):1013-22. PubMed ID: 17327489
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and evaluation of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-aminopropanamide as human cannabinoid-1 receptor (CB1R) inverse agonists.
Du W; Jewell JP; Lin LS; Colandrea VJ; Xiao JC; Lao J; Shen CP; Bateman TJ; Reddy VB; Ha SN; Shah SK; Fong TM; Hale JJ; Hagmann WK
Bioorg Med Chem Lett; 2009 Sep; 19(17):5195-9. PubMed ID: 19632830
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and cannabinoid-1 receptor binding affinity of conformationally constrained analogs of taranabant.
Kopka IE; Lin LS; Jewell JP; Lanza TJ; Fong TM; Shen CP; Lao ZJ; Ha S; Castonguay LG; Van der Ploeg L; Goulet MT; Hagmann WK
Bioorg Med Chem Lett; 2010 Aug; 20(16):4757-61. PubMed ID: 20643546
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo metabolism of a novel cannabinoid-1 receptor inverse agonist, taranabant, in rats and monkeys.
Reddy VB; Doss GA; Karanam BV; Samuel K; Lanza TJ; Lin LS; Yu NX; Zhang AS; Raab CE; Stearns RA; Kumar S
Xenobiotica; 2010 Sep; 40(9):650-62. PubMed ID: 20608842
[TBL] [Abstract][Full Text] [Related]
6. Metabolism and excretion of [14C]taranabant, a cannabinoid-1 inverse agonist, in humans.
Karanam B; Addy C; Bateman T; Reddy VB; Li S; Dean D; Li H; Jones A; Schenk D; Zhang AS; Braun M; Freeman A; Flach S; Stoch A; Chodakewitz J; Wagner JA; Kumar S
Xenobiotica; 2010 Oct; 40(10):691-700. PubMed ID: 20722472
[TBL] [Abstract][Full Text] [Related]
7. Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.
Lin LS; Lanza TJ; Jewell JP; Liu P; Shah SK; Qi H; Tong X; Wang J; Xu SS; Fong TM; Shen CP; Lao J; Xiao JC; Shearman LP; Stribling DS; Rosko K; Strack A; Marsh DJ; Feng Y; Kumar S; Samuel K; Yin W; Van der Ploeg LH; Goulet MT; Hagmann WK
J Med Chem; 2006 Dec; 49(26):7584-7. PubMed ID: 17181138
[TBL] [Abstract][Full Text] [Related]
8. The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake.
Addy C; Wright H; Van Laere K; Gantz I; Erondu N; Musser BJ; Lu K; Yuan J; Sanabria-Bohórquez SM; Stoch A; Stevens C; Fong TM; De Lepeleire I; Cilissen C; Cote J; Rosko K; Gendrano IN; Nguyen AM; Gumbiner B; Rothenberg P; de Hoon J; Bormans G; Depré M; Eng WS; Ravussin E; Klein S; Blundell J; Herman GA; Burns HD; Hargreaves RJ; Wagner J; Gottesdiener K; Amatruda JM; Heymsfield SB
Cell Metab; 2008 Jan; 7(1):68-78. PubMed ID: 18177726
[TBL] [Abstract][Full Text] [Related]
9. The discovery of taranabant, a selective cannabinoid-1 receptor inverse agonist for the treatment of obesity.
Hagmann WK
Arch Pharm (Weinheim); 2008 Jul; 341(7):405-11. PubMed ID: 18574849
[TBL] [Abstract][Full Text] [Related]
10. Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesity.
Yan L; Huo P; Debenham JS; Madsen-Duggan CB; Lao J; Chen RZ; Xiao JC; Shen CP; Stribling DS; Shearman LP; Strack AM; Tsou N; Ball RG; Wang J; Tong X; Bateman TJ; Reddy VB; Fong TM; Hale JJ
J Med Chem; 2010 May; 53(10):4028-37. PubMed ID: 20423086
[TBL] [Abstract][Full Text] [Related]
11. Discovery of N-{(1S,2S)-2-(3-cyanophenyl)- 3-[4-(2-[18F]fluoroethoxy)phenyl]-1-methylpropyl}- 2-methyl-2-[(5-methylpyridin-2-yl)oxy]propanamide, a cannabinoid-1 receptor positron emission tomography tracer suitable for clinical use.
Liu P; Lin LS; Hamill TG; Jewell JP; Lanza TJ; Gibson RE; Krause SM; Ryan C; Eng W; Sanabria S; Tong X; Wang J; Levorse DA; Owens KA; Fong TM; Shen CP; Lao J; Kumar S; Yin W; Payack JF; Springfield SA; Hargreaves R; Burns HD; Goulet MT; Hagmann WK
J Med Chem; 2007 Jul; 50(15):3427-30. PubMed ID: 17608398
[TBL] [Abstract][Full Text] [Related]
12. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers.
Addy C; Li S; Agrawal N; Stone J; Majumdar A; Zhong L; Li H; Yuan J; Maes A; Rothenberg P; Cote J; Rosko K; Cummings C; Warrington S; Boyce M; Gottesdiener K; Stoch A; Wagner J
J Clin Pharmacol; 2008 Apr; 48(4):418-27. PubMed ID: 18258750
[TBL] [Abstract][Full Text] [Related]
13. Homology models of the cannabinoid CB1 and CB2 receptors. A docking analysis study.
Montero C; Campillo NE; Goya P; Páez JA
Eur J Med Chem; 2005 Jan; 40(1):75-83. PubMed ID: 15642412
[TBL] [Abstract][Full Text] [Related]
14. The cannabinoid-1 receptor inverse agonist taranabant reduces abdominal pain and increases intestinal transit in mice.
Fichna J; Sibaev A; Sałaga M; Sobczak M; Storr M
Neurogastroenterol Motil; 2013 Aug; 25(8):e550-9. PubMed ID: 23692073
[TBL] [Abstract][Full Text] [Related]
15. Taranabant, a novel cannabinoid type 1 receptor inverse agonist.
Fremming BA; Boyd ST
Curr Opin Investig Drugs; 2008 Oct; 9(10):1116-29. PubMed ID: 18821475
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and activity of 1,3,5-triphenylimidazolidine-2,4-diones and 1,3,5-triphenyl-2-thioxoimidazolidin-4-ones: characterization of new CB1 cannabinoid receptor inverse agonists/antagonists.
Muccioli GG; Wouters J; Charlier C; Scriba GK; Pizza T; Di Pace P; De Martino P; Poppitz W; Poupaert JH; Lambert DM
J Med Chem; 2006 Feb; 49(3):872-82. PubMed ID: 16451053
[TBL] [Abstract][Full Text] [Related]
17. Influence of taranabant, an orally active, highly selective, potent cannabinoid-1 receptor (CB1R) inverse agonist, on ethinyl estradiol and norelgestromin plasma pharmacokinetics.
Schwartz JI; Dunbar S; Yuan J; Li S; Miller DL; Rosko K; Johnson-Levonas AO; Lasseter KC; Wagner JA
J Clin Pharmacol; 2009 Jan; 49(1):72-9. PubMed ID: 18936284
[TBL] [Abstract][Full Text] [Related]
18. Development of a 3D model for the human cannabinoid CB1 receptor.
Salo OM; Lahtela-Kakkonen M; Gynther J; Järvinen T; Poso A
J Med Chem; 2004 Jun; 47(12):3048-57. PubMed ID: 15163186
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists.
Lange JH; Coolen HK; van Stuivenberg HH; Dijksman JA; Herremans AH; Ronken E; Keizer HG; Tipker K; McCreary AC; Veerman W; Wals HC; Stork B; Verveer PC; den Hartog AP; de Jong NM; Adolfs TJ; Hoogendoorn J; Kruse CG
J Med Chem; 2004 Jan; 47(3):627-43. PubMed ID: 14736243
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, safety, and tolerability of phentermine in healthy participants receiving taranabant, a novel cannabinoid-1 receptor (CB1R) inverse agonist.
Addy C; Jumes P; Rosko K; Li S; Li H; Maes A; Johnson-Levonas AO; Chodakewitz J; Stoch SA; Wagner JA
J Clin Pharmacol; 2009 Oct; 49(10):1228-38. PubMed ID: 19783715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]